Navigation Links
Biolaxy Secures IND Approval for Oral Insulin
Date:11/24/2009

SHANGHAI, Nov. 24 /PRNewswire-Asia/ -- Shanghai Biolaxy announced the Chinese State Food & Drug Administration (SFDA) has approved the investigational new drug application (IND) for its oral insulin project (Nodlin), an innovative insulin formulation to treat diabetes. This IND approval allows Biolaxy to initiate its first phase I clinical study.

Diabetes is a disorder characteristic of high blood glucose and poor metabolism. The complications of diabetes often result in severe micro- and macro-vascular diseases, loss of vision, kidney failure, and amputation. Insulin, as an effective diabetic treatment, can slow down diabetic disease progression. However, insulin is given by multiple daily injections at present, which significantly hinders its use.

Oral drug administration is a preferred route. However, the gastrointestinal (GI) tract is designed to digest nutrients like proteins and presents significant challenges for oral insulin including enzyme degradation and poor absorption. Currently, there is no approved oral insulin product despite intensive research in this field.

Nodlin is developed with NOD technology, a patented bio-adhesive nano-particle oral delivery technology, to overcome the barriers of oral insulin.

"IND approval is a significant milestone achievement for Biolaxy," quoted from William Lee, CEO. "We have experienced long delay in the approval process due to regulatory uncertainties, but we are very happy now Biolaxy is back on track in full speed to develop urgently needed drugs for the patients."

    For more information, please contact:

     William Lee, Ph.D., CEO
     Phone: +86-21-6194-0758
     Email: info@biolaxy.com

    Press Contact
     Qianyu Zhao, Ph.D., Director of R&D
     Phone: +86-21-6194-0858 x807
     Email: info@biolaxy.com


    Notes for Editors

About Diabetes and Insulin Treatment

Diabetes has reached epidemic stage. It is estimated that there are 30-40 million diabetic patients in China with 1.2 million new cases each year. Insulin is a key diabetic treatment with worldwide market value close to $10 billion. Diabetic patients have to endure multiple daily injections for life and patients often are reluctant to use insulin despite the clinical proven benefits of early insulin treatment. Currently, insulin treatment in China particularly is under used.

About Biolaxy

Shanghai Biolaxy is a development stage biotech company and emerging leader in innovative delivery for biopharmaceuticals. Biolaxy was established in 2005 and is a wholly owned subsidiary of NOD Pharmaceuticals. Biolaxy uses patented platform technology, nano-particle oral delivery or NOD technology, to develop oral formulations for biopharmaceuticals, including insulin, exenatide, interferon, human growth hormone and more.

Nodlin is the first candidate developed with NOD technology and is positioned as basal insulin formulation based on the pre-clinical data. Nodlin possesses unique pharmacokinetic profile and is highly competitive.

More information can be found at http://www.biolaxy.com .

SOURCE Shanghai Biolaxy


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotech Secures 10-Year Tissue Supply Agreement
2. Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
3. Corgenix Secures $1,750,000 Asset Based Credit Facility Representing Initial Gross Proceeds of $1.109 Million
4. LS9 Secures $25 Million in Latest Round of Funding
5. Neurocrine Biosciences Secures Committed Equity Financing Facility
6. OpenQ Secures Investment from Leading Mid-Atlantic Venture Firm
7. Cappella Inc. Secures $17.3 Million Series C Investment
8. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria
9. Sinobiopharma Secures Rights to Seven Key Patents
10. Aerovance Secures $38 Million in Equity Financing
11. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016 Australian-US drug discovery and development ... the appointment of a new Chairman, Mr John O,Connor ... effective immediately. James Garner , has also ... and former Acting CEO, Mr Iain Ross , will ... --> James Garner , has also been formally ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... Bloomsburg University’s Digital Forensics Club, takes place February 5-6 at the University’s ... 20+ speakers and activities such as workshops and competitions for ample networking, ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016 ContraVir ... focused on the development and commercialization of targeted antiviral ... CEO & Investor Conference 2016, to be held February ... Source Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... on February 10-11, 2016. James Sapirstein , ...
(Date:2/4/2016)... ... ... Many of the engineers at FireflySci, Inc. have been manufacturing quartz and ... other cuvette manufacturers is their supercharged customer service and their extensive database of glass ... flow of inside information, they have recently revamped their manufacturing techniques to reduce lead ...
Breaking Biology Technology:
(Date:2/1/2016)... Feb. 1, 2016  Today, the first day of ... plans to develop a first of its kind workplace ... IBM Watson. In the first application of ... IBM ), and Welltok will create a new ... with cognitive analytics, delivered on Welltok,s health optimization platform. ...
(Date:1/25/2016)... 2016   Unisys Corporation (NYSE: UIS ) today ... (JFK) International Airport, New York City , to ... attempting to enter the United States using ... pilot testing of the system at Dulles last year. ... JFK during January 2016. --> pilot testing of ...
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
Breaking Biology News(10 mins):